Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04932434
PHASE2

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease

Sponsor: Joshua Woolley, MD, PhD

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.

Official title: Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study

Key Details

Gender

All

Age Range

40 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2021-08-15

Completion Date

2024-12-31

Last Updated

2026-09-03

Healthy Volunteers

No

Interventions

DRUG

Psilocybin therapy

* Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring * Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring

Locations (1)

University of California, San Francisco

San Francisco, California, United States